Cargando…

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers

To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial ovarian cancer. METHODS: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. RESULTS: Because of its low sensitivity (50...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sölétormos, György, Duffy, Michael J., Othman Abu Hassan, Suher, Verheijen, René H.M., Tholander, Bengt, Bast, Robert C., Gaarenstroom, Katja N., Sturgeon, Catharine M., Bonfrer, Johannes M., Petersen, Per Hyltoft, Troonen, Hugo, CarloTorre, Gian, Kanty Kulpa, Jan, Tuxen, Malgorzata K., Molina, Raphael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Ovarian Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679342/ https://www.ncbi.nlm.nih.gov/pubmed/26588231 http://dx.doi.org/10.1097/IGC.0000000000000586

Ejemplares similares

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved
por: Vallino, Letizia, et al.
Publicado: (2020)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period
por: Abu Hassan, Suher O, et al.
Publicado: (2017)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells
por: Ha, Ji Hee, et al.
Publicado: (2020)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wang, Haihong, et al.
Publicado: (2018)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center
por: Alwazzan, Ahmad Bakr, et al.
Publicado: (2015)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience
por: Zhao, Jianguo, et al.
Publicado: (2018)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

New ways of assessing ovarian cancer response: metabolic imaging and beyond
por: Rockall, Andrea, et al.
Publicado: (2012)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
por: Wojcik, Ewa, et al.
Publicado: (2017)

A radiomic nomogram based on arterial phase of CT for differential diagnosis of ovarian cancer
por: Hu, Yumin, et al.
Publicado: (2021)

Updates on fluorescent probes and open‐field imaging methods for fluorescence‐guided cytoreductive surgery for epithelial ovarian cancer: A review
por: Sun, Chongen, et al.
Publicado: (2022)

High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer
por: Wu, Xiaodong, et al.
Publicado: (2022)

Preoperative radiotherapy does not alter pre- and early postoperative serum C-reactive protein and albumin concentrations in colorectal cancer patients
por: Wysocki, Wojciech M., et al.
Publicado: (2013)

Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
por: Pandey, Avinash, et al.
Publicado: (2016)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer
por: Kristiansen, Søren, et al.
Publicado: (2016)

Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience
por: Mituś, Jerzy Władysław, et al.
Publicado: (2013)

Ovarian cancer: state of the art and perspectives of clinical research
por: Boussios, Stergios, et al.
Publicado: (2020)

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
por: Kristiansen, Søren, et al.
Publicado: (2015)

RoBERTa-Assisted Outcome Prediction in Ovarian Cancer Cytoreductive Surgery Using Operative Notes
por: Laios, Alexandros, et al.
Publicado: (2023)

Metformin and ovarian cancer: the evidence
por: Urpilainen, Elina, et al.
Publicado: (2020)

Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk.
por: Bruning, P. F., et al.
Publicado: (1985)

Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS)
por: Kimmig, Rainer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9d5vflguv1e112ll90mkg126er